Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

Effector cells derived from central memory CD8+ T cells were reported to engraft and survive better than those derived from effector memory populations, suggesting that they are superior for use in adoptive immunotherapy studies. However, previous studies did not evaluate the relative efficacy of effector cells derived from naïve T cells. We sought to investigate the efficacy of tumor-specific effector cells derived from naïve or central memory T-cell subsets using transgenic or retrovirally transduced T cells engineered to express a tumor-specific T-cell receptor. We found that naïve, rather than central memory T cells, gave rise to an effector population that mediated superior antitumor immunity upon adoptive transfer. Effector cells developed from naïve T cells lost the expression of CD62L more rapidly than those derived from central memory T cells, but did not acquire the expression of KLRG-1, a marker for terminal differentiation and replicative senescence. Consistent with this KLRG-1− phenotype, naïve-derived cells were capable of a greater proliferative burst and had enhanced cytokine production after adoptive transfer. These results indicate that insertion of genes that confer antitumor specificity into naïve rather than central memory CD8+ T cells may allow superior efficacy upon adoptive transfer.

[1]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[2]  D. Voehringer,et al.  Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.

[3]  P. Marrack,et al.  Identification of two major types of age-associated CD8 clonal expansions with highly divergent properties , 2008, Proceedings of the National Academy of Sciences.

[4]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[5]  N. Restifo,et al.  Programming CD8+ T cells for effective immunotherapy. , 2006, Current opinion in immunology.

[6]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Liu,et al.  Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. , 2008, The Journal of clinical investigation.

[8]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[9]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[10]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[11]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[12]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Kaech,et al.  Expression of IL-7 receptor α is necessary but not sufficient for the formation of memory CD8 T cells during viral infection , 2007, Proceedings of the National Academy of Sciences.

[14]  P. Hanley,et al.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. , 2009, Blood.

[15]  E. Wherry,et al.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.

[16]  R. Ahmed,et al.  Differentiation of memory B and T cells. , 2006, Current opinion in immunology.

[17]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[18]  V. Appay,et al.  CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.

[19]  B. Thiers,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2008 .

[20]  P. Marrack,et al.  CD4 memory T cells divide poorly in response to antigen because of their cytokine profile , 2008, Proceedings of the National Academy of Sciences.

[21]  C. June,et al.  Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.

[22]  P. Muranski,et al.  Type 17 CD8+ T cells display enhanced antitumor immunity. , 2009, Blood.

[23]  P. Marrack,et al.  CD4 memory T cells: what are they and what can they do? , 2009, Seminars in immunology.

[24]  L. Picker,et al.  Addendum: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge , 2011, Nature Medicine.

[25]  S. J. Griffiths,et al.  KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. , 2009, Blood.

[26]  Chung-Che Chang,et al.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. , 2007, Blood.

[27]  T. Schumacher,et al.  Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. , 2007, Blood.

[28]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Mosmann,et al.  Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. , 1995, Immunity.

[30]  W. Leonard,et al.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.

[31]  Victor Appay,et al.  Lessons from the study of T-cell differentiation in persistent human virus infection. , 2004, Seminars in immunology.

[32]  S. Rosenberg,et al.  Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. , 2008, Human gene therapy.

[33]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[34]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[35]  C. Turtle,et al.  Adoptive transfer of virus-specific and tumor-specific T cell immunity. , 2009, Current opinion in immunology.

[36]  S. Rosenberg,et al.  Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity , 2008, Proceedings of the National Academy of Sciences.

[37]  P. Hwu,et al.  Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy , 2007, Clinical Cancer Research.

[38]  M. Shinohara,et al.  Analysis of regulatory CD8 T cells in Qa-1-deficient mice , 2004, Nature Immunology.

[39]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[40]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[41]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[42]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[43]  E. Wherry,et al.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.